Literature DB >> 12780665

Steroid-free immunosuppression during and after liver transplantation--a 3-yr follow-up report.

Jacques Pirenne1, Raymond Aerts, Takaaki Koshiba, Frank Van Gelder, Tania Roskams, Marie Schetz, Marleen Verhaegen, Peter Lauwers, Johan Fevery, Frederik Nevens.   

Abstract

BACKGROUND/AIMS: Steroids are traditionally used in liver transplantation as a part of a triple or quadruple immunosuppressive regimen. Steroids act non-specifically and cause multiple side-effects. Most liver transplantation centers reduce the dosage of steroids and eventually withdraw them after various time intervals. A few steroid-free trials have been recently conducted after liver transplantation but long-term data are not yet available. In addition, in these trials steroids were usually given during surgery. We report the long-term (median = 40 months) follow-up data of a prospective pilot study designed to determine whether liver transplantation could be performed with no steroids at all (neither during nor after surgery).
METHODS: Twenty-one consecutive liver transplantations in 20 adult patients between August 1998 and July 1999 were prospectively included in an ab initio steroid-free immunosuppressive protocol. Mean age was 54 yr (40-67 yr). Tacrolimus (through levels, 8-10 ng/mL) and azathioprine (1-2 mg/kg) were started after liver transplantation. Patients were not given steroids during or after liver transplantation except in the event of rejection or in case of tacrolimus or azathioprine toxicity requiring significant dose reduction and/or withdrawal.
RESULTS: There has been no case of primary graft dysfunction or non-function. Eleven of 21 liver transplantations (52%) received no steroids throughout the whole study. Rejection developed in five of 21 liver transplantations (23.5%). These rejections responded to standard i.v. steroids (plus ATG in one patient), followed by an oral steroid taper stopped 3 months after rejection. Steroids were transiently given in six liver transplantations for non-immune reasons: two with tacrolimus-induced neurotoxicity, three cases where azathioprine was discontinued, and one for an allergic reaction; four of these six patients are off steroids at last follow-up. The 3-yr graft and patient survival is 95 and 100%, respectively.
CONCLUSIONS: Steroids are not necessary in more than 50% of liver transplantations. Steroids were transiently needed to treat acute rejection in 23.5% liver transplantations and for toxicity of calcineurin inhibitors or azathioprine or other reason in 28%. Of the patients who received steroids, the majority (70%) was eventually taken off steroids. This prospective single-center pilot study shows that liver transplantation without steroids is feasible and yields no penalty in terms of acute and chronic rejection, immune graft loss, graft function, patient and graft survival.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12780665     DOI: 10.1034/j.1399-0012.2003.00017.x

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  6 in total

Review 1.  Corticosteroid-free strategies in liver transplantation.

Authors:  John G O'Grady
Journal:  Drugs       Date:  2006       Impact factor: 9.546

2.  Early steroid withdrawal after liver transplantation for hepatocellular carcinoma.

Authors:  Zhi-Shui Chen; Fan He; Fan-Jun Zeng; Ji-Pin Jiang; Dun-Feng Du; Bin Liu
Journal:  World J Gastroenterol       Date:  2007-10-21       Impact factor: 5.742

3.  Late-onset acute rejection after living donor liver transplantation.

Authors:  Nobuhisa Akamatsu; Yasuhiko Sugawara; Sumihito Tamura; Junichi Keneko; Yuichi Matsui; Kiyoshi Hasegawa; Masatoshi Makuuchi
Journal:  World J Gastroenterol       Date:  2006-11-07       Impact factor: 5.742

4.  A prospective, randomized trial of complete avoidance of steroids in liver transplantation with follow-up of over 7 years.

Authors:  Shawn J Pelletier; Satish N Nadig; David D Lee; John B Ammori; Michael J Englesbe; Randall S Sung; John C Magee; Robert J Fontana; Jeffrey D Punch
Journal:  HPB (Oxford)       Date:  2012-09-28       Impact factor: 3.647

5.  Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  Robert P Baughman; Keith C Meyer; Ian Nathanson; Luis Angel; Sangeeta M Bhorade; Kevin M Chan; Daniel Culver; Christopher G Harrod; Mary S Hayney; Kristen B Highland; Andrew H Limper; Herbert Patrick; Charlie Strange; Timothy Whelan
Journal:  Chest       Date:  2012-11       Impact factor: 9.410

Review 6.  Role of steroid minimization in the tacrolimus-based immunosuppressive regimen for liver transplant recipients: a systematic review and meta-analysis of prospective randomized controlled trials.

Authors:  Jinyang Gu; Xingyu Wu; Lei Lu; Shu Zhang; Jianling Bai; Jun Wang; Jun Li; Yitao Ding
Journal:  Hepatol Int       Date:  2014-03-20       Impact factor: 6.047

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.